Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Zenas BioPharma, Inc. Common Stock (ZBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ZBIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $32.14
1 Year Target Price $32.14
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -47.8% | Avg. Invested days 26 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 460.59M USD | Price to earnings Ratio - | 1Y Target Price 32.14 |
Price to earnings Ratio - | 1Y Target Price 32.14 | ||
Volume (30-day avg) 7 | Beta - | 52 Weeks Range 5.83 - 26.25 | Updated Date 05/20/2025 |
52 Weeks Range 5.83 - 26.25 | Updated Date 05/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.89 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -373.3% |
Management Effectiveness
Return on Assets (TTM) -56.7% | Return on Equity (TTM) -115.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 110831343 | Price to Sales(TTM) 30.71 |
Enterprise Value 110831343 | Price to Sales(TTM) 30.71 | ||
Enterprise Value to Revenue 22.17 | Enterprise Value to EBITDA - | Shares Outstanding 41834200 | Shares Floating 20950558 |
Shares Outstanding 41834200 | Shares Floating 20950558 | ||
Percent Insiders 21.2 | Percent Institutions 74.81 |
Analyst Ratings
Rating 3 | Target Price 32.14 | Buy 2 | Strong Buy 5 |
Buy 2 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Zenas BioPharma, Inc. Common Stock
Company Overview
History and Background
Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of meaningfully differentiated therapies for patients suffering from autoimmune diseases.
Core Business Areas
- Immunology: Focuses on developing therapies to treat autoimmune diseases.
Leadership and Structure
Details about Zenas BioPharma's leadership team and organizational structure can be found on their investor relations website, which includes executive bios and board members. It is publicly traded.
Top Products and Market Share
Key Offerings
- Obexelimab: Obexelimab is Zenas BioPharma's leading product candidate, a novel B-cell modulating antibody. It is in clinical trials for treating autoimmune diseases, but does not yet have market share. Competitors include Roche (RHHBY), Bristol Myers Squibb (BMY), and Johnson & Johnson (JNJ) with their respective autoimmune disease therapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing growth driven by innovation in drug development and increased demand for treatments for chronic diseases.
Positioning
Zenas BioPharma aims to position itself as a key player in the autoimmune disease treatment market through its innovative B-cell modulating antibody.
Total Addressable Market (TAM)
The autoimmune disease market is estimated to be billions of dollars. Zenas BioPharma's position within the TAM is based on the clinical success and commercialization of Obexelimab and other pipeline products. Data not fully available but the global autoimmune disease diagnostics market is estimated to reach US$ 24.7 Billion by 2032.
Upturn SWOT Analysis
Strengths
- Novel B-cell modulating antibody
- Experienced management team
- Focus on autoimmune diseases
Weaknesses
- Limited commercialized products
- Reliance on clinical trial success
- Competition from larger pharmaceutical companies
Opportunities
- Successful clinical trial outcomes
- Expansion into new autoimmune disease indications
- Partnerships and collaborations
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established therapies
- Patent disputes
Competitors and Market Share
Key Competitors
- Roche (RHHBY)
- Bristol Myers Squibb (BMY)
- Johnson & Johnson (JNJ)
Competitive Landscape
Zenas BioPharma is in a competitive market against companies with established autoimmune disease therapies. Its advantage lies in its novel B-cell modulating antibody.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily in terms of pipeline development and clinical trial progress.
Future Projections: Future growth projections depend on the successful development and commercialization of Obexelimab and other pipeline products. These are available from analyst reports.
Recent Initiatives: Recent initiatives include ongoing clinical trials and potential partnerships.
Summary
Zenas BioPharma is a clinical-stage biopharmaceutical company focused on autoimmune diseases. Its success hinges on the development and commercialization of its lead product, Obexelimab. The company faces competition from larger, established pharmaceutical companies. Successful clinical trials and strategic partnerships are critical for its growth. Financial performance is currently driven by investment in R&D rather than product sales.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Zenas BioPharma's Investor Relations website
- SEC Filings (10-K, 10-Q)
- Industry reports
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zenas BioPharma, Inc. Common Stock
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2024-09-13 | CEO & Chairman of the Board Mr. Leon Oliver Moulder Jr., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 130 | Website https://zenasbio.com |
Full time employees 130 | Website https://zenasbio.com | ||
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.